6-K ·Filed Jul 9, 2026

RDY

DR REDDYS LABORATORIES LTD
BEARISH
Impact 5/10
Horizonweeks Processed2mo ago SEC0001575872-26-000489
Notable filing: 6-K
Actionable Insight ▼ Bearish

Monitor the conference call for root cause and timeline. The delay could allow competitors to capture market share in the generic semaglutide space. Assess if Dr. Reddy's revises guidance in upcoming quarters.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
RDY ▼ -12.81% at T+20d
SHORT call ✓ call won +12.81% · α vs SPY +15.06% · entry $13.89 → $12.11
Next anchor: T+60d due 8h ago
Latest observation: T+57 +7.76% FF3 residual α
Entry anchored
Jul 8, 03:59 PM ET
via exchange tick
T+1d
-5.04%
call +5.04% · α +5.47%
$13.19
settled 3mo ago
T+5d
-8.57%
call +8.57% · α +8.44%
$12.70
settled 3mo ago
T+20d
-12.81%
call +12.81% · α +15.06%
$12.11
settled 8w ago
T+60d
—
call — · α —
—
due 8h ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's disclosed that certain batches of semaglutide (a key metabolic therapy) were found out of specification due to an API issue, delaying commercial supplies until the root cause is resolved. No patient safety impact or effect on existing regulatory filings, but the delay creates near-term revenue uncertainty for a high-demand product.

Key Facts

  • Semaglutide batches out of specification due to API issue
  • Commercial supplies delayed until root cause resolved
  • No impact on patient safety or existing global regulatory filings
  • Management conference call scheduled for July 9, 2026 at 16:30 IST

Financial Impact

Commercial delay of semaglutide; undisclosed revenue exposure as no financial figures provided in filing

revenueproduct supply

Risk Factors

  • Extended delay could impair competitive positioning
  • Potential regulatory scrutiny or remediation costs
  • Revenue shortfall if semaglutide was a near-term growth driver

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000489
Document: 0001575872-26-000489-index.html0001575872-26-000489
Document: 0001575872-26-000489.txt0001575872-26-000489
51 reports for RDY
Performance horizon
63% Hit rate 5 of 8 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access